Screening
Adoption of high content screening at HTS laboratories
Over the past five years, a majority of HTS laboratories have adopted high content screening (HCS) in their operations. As HTS laboratories have sought more biologically-relevant assays, cell-based assays and high content screening technologies have become more widespread.
H
ighTech Business Decisions’ latest report, (High Content Screening 2013: Expanded Use and Improved Technologies), shows the adoption rate of HCS has increased over the past five years. In 2012, 61% of the HTS laboratories incorporated HCS in their operations, compared to 40% in 2007 (Figure 1). Improvements in through- puts, system capabilities, data handling and analysis have to increase the adoption of HCS. While barri- ers to adoption remain (eg, costs, throughput, etc), both HTS laboratories and their suppliers continue to dedicate resources to improve HCS technologies. While HCS adoption has increased over the past five years, its rate of adoption has not been uni- form across the various types of organisations that operate HTS laboratories. In order to obtain a bet- ter understanding of the adoption of HCS tech- nologies by HTS laboratories, we have segmented the HTS laboratories into three different categories based on the type of organisation to which they belong. For our analysis, the HTS laboratories are categorised into three segments: a) academic or government-sponsored laboratory, b) pharmaceuti- cal and biotechnology companies, and c) contract research organisations. We define academic HTS laboratories as those that operate under either a university or a government entity. Pharmaceutical
Drug Discovery World Spring 2013
and biotechnology HTS laboratories belong to innovative drug companies developing therapeutics or diagnostics. The third segment includes contract research organisations (CRO) that provide fee-for- service screening to clients. From our study, more than three-quarters of the academic laboratories have adopted HCS technolo- gies, while slightly over half of the pharma/biotech HTS laboratories use HCS technologies in their high throughput screening operations. While a majority of academic and pharma/biotech has adopted some HCS technologies, a minority of con- tract research organisations uses HCS technologies. From our study, approximately one-quarter of the contract research organisations use HCS technolo- gies in their laboratories (Figure 2).
HCS activities in HTS operations For the HTS laboratories that have adopted HCS technologies, slightly less than half of those HTS laboratories use HCS in multiple areas of drug dis- covery (Figure 3). Most HTS laboratories run high content screens for secondary screens or hit valida- tion (84%), while 48% of the HTS laboratories use HCS for primary screening. Other areas where HCS is used include lead optimisation, compound profiling and toxicity studies (Figure 4).
51
By William Downey and Dr Jennifer Hartigan
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80